Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
|
30834837 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis.
|
30191589 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneously, DNA gyrase targeted drugs are particularly attractive in the treatment of tuberculosis as DNA gyrase is the sole type II topoisomerase in Mycobacterium tuberculosis.
|
29110590 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Broadened antibacterial activity was introduced to rhodanine derivatives targeting Mycobacterial tuberculosis enoyl-acyl carrier protein reductase (Mtb InhA) by recruiting feature of xacins to bring DNA Gyrase B inhibitory capability.
|
30713272 |
2019 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The initial evidence that DNA gyrase might be the target of QOAs, based on high minimum inhibitory concentration (MIC) values against ofloxacin-resistant clinical isolates and structural similarities with fluoroquinolones, was discarded by experiments performed with M. tuberculosis GyrA point mutant, DNA gyrase supercoiling inhibition assay and overexpression of DNA gyrase.
|
28843821 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
|
28071975 |
2018 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using ChIP-Seq, we show the genome-wide occupancy profile of both topoisomerase I and DNA gyrase in conjunction with RNAP in Mycobacterium tuberculosis taking advantage of minimal topoisomerase representation in the organism.
|
28463980 |
2017 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the exploitation of topoisomerases as antibacterial targets and summarize progress in developing new agents to target DNA topoisomerase I and DNA gyrase from Mycobacterium tuberculosis.
|
27856347 |
2017 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Double Mutants in DNA Gyrase Lead to Ofloxacin Resistance in Mycobacterium tuberculosis.
|
28247939 |
2017 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA gyrase mutations are a major cause of quinolone resistance in Mycobacterium tuberculosis We therefore conducted the first comprehensive study to determine the diversity of gyrase mutations in pre-extensively drug-resistant (pre-XDR) (n = 71) and extensively drug-resistant (XDR) (n = 30) Thai clinical tuberculosis (TB) isolates.
|
27297489 |
2016 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The mutation was identified in five isolates without DNA gyrase mutations and three isolates with such mutations; it was identified in both European-American and East Asian M. tuberculosis lineages.
|
27261264 |
2016 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The DNA topoisomerases are excellent targets for chemotherapy, and DNA gyrase in particular is a well-validated target for antibacterial agents.Naphthoquinones (e.g. diospyrin and 7-methyljuglone) have been shown to have therapeutic potential, particularly against Mycobacterium tuberculosis.
|
23275348 |
2013 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the mutation types of the genes encoding the A and B subunits of DNA gyrase (gyrA and gyrB, respectively) in ofloxacin- and levofloxacin-resistant Mycobacterium tuberculosis strains prevalent in mainland China, 177 clinical drug-resistant isolates collected by the National Tuberculosis Reference Laboratory of China were analysed.
|
22526012 |
2012 |
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main mechanism of FQ resistance is amino acid substitution within the quinolone resistance-determining region (QRDR) of the GyrA subunit of DNA gyrase, the sole FQ target in M. tuberculosis.
|
22290942 |
2012 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
|
22421328 |
2012 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a systematic review of studies reporting mutations in DNA gyrase genes in clinical M. tuberculosis isolates.
|
22279180 |
2012 |
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
|
21768507 |
2011 |